



# **iJRASET**

International Journal For Research in  
Applied Science and Engineering Technology



---

# **INTERNATIONAL JOURNAL FOR RESEARCH**

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

---

**Volume:** 13    **Issue:** VI    **Month of publication:** June 2025

**DOI:** <https://doi.org/10.22214/ijraset.2025.72608>

**[www.ijraset.com](http://www.ijraset.com)**

**Call:** ☎ 08813907089

**E-mail ID:** [ijraset@gmail.com](mailto:ijraset@gmail.com)

# Therapeutic Potential of Yashtimadhu (*Glycyrrhiza glabra*) in Demyelinating Disorders: An Ayurvedic Perspective

Dr. Kumari Triveni<sup>1</sup>, Dr. Rajashekar S Ganiger<sup>2</sup>, Dr. Shivanand Karigar<sup>3</sup>

<sup>1</sup>III<sup>rd</sup> year PG scholar, <sup>2</sup>HOD and Prof, <sup>3</sup>Assistant Prof, Department of dravyaguna, TGAMC, Ballari, RGUHS Karnataka

**Abstract:** Demyelination involves the progressive destruction of the myelin sheath, leading to neurological impairment. In Ayurveda, such conditions correlate with Majja Dhatu Kshaya and Vata Vyadhi, particularly Pakshaghata, Ardita, and Kampavata. Yashtimadhu (*Glycyrrhiza glabra*), a Medhya Rasayana, has been traditionally used for Majjaposhana (nourishment of the nerve/marrow tissue), Vata shamanam, and balyakarma. This presentation is intended to evaluate the therapeutic role of Yashtimadhu in the context of demyelinating neurological conditions. **Method-**Textual analysis from classical Ayurvedic compendia (Charaka Samhita, Ashtanga Hridaya, Bhavaprakasha) and supportive data from experimental and pharmacological literature were reviewed. **Result and Discussion-**Yastimadhu is described in ayurveda as balya, medhya, rasayana and vatapittahara making it a suitable drug in demyelination disorder. In this condition we need a drug which repairs myelin, restores nerve signal, rejuvenates tissue, reduce inflammation and improves immunity in ayurvedic terminology we need a drug which does majja dhatu poshana, vatashamana, rasayana therapy, pitta vata pacification and ojasvardhana respectively. Yastimadhu is one drug which can do all these work by its anti-inflammatory action, antioxidant and neuroprotective action as rich in flavanoids and saponin, balances immune system, promotes tissue regeneration and healing. **Conclusion -**Yastimadhu through its majja dhatu poshana, rasyana and vatashamaka action presents as a promising ayurvedic intervention in demyelination condition.

**Keywords:** Yastimadhu, Demyelinating disorders, Myelin Repair, Neuroprotective.

## I. INTRODUCTION

Demyelinating disorders are neurological conditions characterized by damage to the myelin sheath, the lipid-rich insulating layer that ensures efficient nerve signal transmission<sup>[1]</sup>. Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), acute disseminated encephalomyelitis (ADEM), and Guillain-Barré syndrome manifest through symptoms such as muscle weakness, spasticity, sensory loss, visual disturbances, cognitive impairment, and fatigue, significantly reducing quality of life<sup>[1]</sup>. Conventional therapies, including corticosteroids, immunosuppressants, and monoclonal antibodies, aim to reduce inflammation and prevent relapses but are limited by side effects (e.g., infections, hepatotoxicity) and minimal impact on remyelination<sup>[2]</sup>. Ayurveda, a 5000-year-old holistic system, emphasizes restoring balance among the three doshas (Vata, Pitta, Kapha), nourishing the seven dhatus (tissues), and enhancing Ojas (vital essence) to promote healing<sup>[3]</sup>. Yashtimadhu (*Glycyrrhiza glabra*), a cornerstone herb in Ayurveda, is celebrated for its Madhura (sweet), Snigdha (unctuous), and Sheeta (cooling) properties, which pacify Vata and Pitta doshas, nourish Majja Dhatu (nervous tissue), and support neural repair<sup>[4]</sup>. This article examines Yashtimadhu's role in addressing demyelination through Ayurvedic principles, supported by pharmacological mechanisms and clinical observations.

## II. METHOD AND MATERIAL

### A. Ayurvedic Pathophysiology of Demyelinating Disorders

In Ayurveda, neurological disorders, including demyelinating conditions, are understood through the lens of doshic imbalances affecting Majja Dhatu (nervous tissue, including the brain, spinal cord, and myelin) and Sira-Snayu (nerves and tendons)<sup>[5]</sup>. Demyelinating disorders can be correlated with Vata-Pitta Sammurchana (combined aggravation of Vata and Pitta), which disrupts the integrity of Majja Dhatu and impairs Ojas, the body's vital essence responsible for immunity and resilience<sup>[6]</sup>.

- 1) **Vata Imbalance:** Vata governs movement, nerve conduction, and sensory functions. Its aggravation, caused by factors like stress, irregular diet, or trauma, leads to Rukshata (dryness), Laghava (lightness), and degeneration of neural tissues, manifesting as tremors, spasticity, or impaired nerve signaling<sup>[5]</sup>.

In demyelination, Vata's drying effect disrupts the lipid-rich myelin sheath, akin to the loss of Snigdha Guna (unctuousness) in Majja Dhatu.

- 2) *Pitta Imbalance*: Pitta regulates metabolism and transformation. Its aggravation, triggered by inflammation, stress, or dietary excesses, causes Ushnata (heat) and Tikshnata (sharpness), leading to inflammatory damage to myelin and neuronal tissues<sup>[7]</sup>. This mirrors the autoimmune and inflammatory processes in MS and NMOSD.
- 3) *Majja Dhatu and Ojas*: Majja Dhatu encompasses the nervous system and bone marrow, providing structural and functional integrity to nerves. Its depletion (MajjaKshaya) due to doshic imbalances results in weakened neural conduction and reduced Ojas, compromising immunity and resilience<sup>[8]</sup>. Demyelination reflects Majja Dhatu Dushti (vitiation), with symptoms like cognitive decline and motordysfunction.

Yashtimadhu's Madhura Rasa (sweet taste), Snigdha Guna (unctuous quality), Sheeta Veerya (cooling potency), and Madhura Vipaka (sweet post-digestive effect) counteract Vata's dryness and Pitta's heat, nourish Majja Dhatu, and restore Ojas<sup>[4]</sup>. Its Balya (strengthening), Jeevaniya (vitalizing), and Medhya (cognition-enhancing) properties, as described in Charaka Samhita and Sushruta Samhita, make it a potent Rasayana for neural repair and regeneration<sup>[5,7]</sup>.

#### B. Yashtimadhu's Role in Addressing Demyelination: Ayurvedic Mechanisms

Yashtimadhu's therapeutic efficacy in demyelinating disorders stems from its ability to address the multifaceted pathophysiology of demyelination through Ayurvedic principles. The following mechanisms highlight how Yashtimadhu supports myelin repair and neural health:

- 1) *Pacification of Vata Dosha*: The myelin sheath, rich in lipids, requires Snigdha (unctuous) and Guru (heavy) qualities to maintain its integrity. Vata's Ruksha (dry) and Laghu (light) nature disrupts this, leading to myelin degradation<sup>[5]</sup>. Yashtimadhu's Snigdha Guna and Madhura Rasa provide nourishment and lubrication to Majja Dhatu, counteracting Vata's drying effect and stabilizing nerve conduction<sup>[4]</sup>. Its unctuous properties mimic the lipid-rich composition of myelin, supporting structural repair.
- 2) *Mitigation of Pitta-Induced Inflammation*: Pitta's inflammatory action damages myelin through Ushnata and Tikshnata, akin to autoimmune attacks in MS<sup>[7]</sup>. Yashtimadhu's Sheeta Veerya cools Pitta, reducing neuroinflammation and protecting myelin from further damage. Its Rasayana properties enhance tissue resilience, preventing recurrent inflammatory episodes<sup>[8]</sup>.
- 3) *Nourishment of Majja Dhatu*: Majja Dhatu is critical for neural integrity and cognitive function. Its depletion leads to symptoms like memory loss and motor deficits<sup>[6]</sup>. Yashtimadhu's Jeevaniya and Balya properties nourish Majja Dhatu, promoting the regeneration of neural tissues, including myelin. Its sweet post-digestive effect supports Dhatu Poshana (tissue nourishment), facilitating myelin repair<sup>[4]</sup>.
- 4) *Enhancement of Ojas*: Ojas is the essence of all dhatus, providing immunity and vitality. Its depletion in demyelinating disorders increases susceptibility to autoimmune attacks<sup>[8]</sup>. Yashtimadhu's Rasayana action strengthens Ojas, enhancing immune resilience and reducing autoimmune activity, thereby supporting long-term neural health<sup>[5]</sup>.
- 5) *Medhya Effect for Cognitive Support*: Cognitive impairment is common in demyelinating disorders due to Majja Dhatu Dushti and Vata aggravation<sup>[7]</sup>. Yashtimadhu's Medhya Rasayana properties enhance cognitive function, memory, and mental clarity, addressing symptoms like brain fog and attention deficits<sup>[3]</sup>.
- 6) *Stress Reduction*: Chronic stress, a Vata-aggravating factor, exacerbates demyelination by disrupting the hypothalamic-pituitary-adrenal (HPA) axis<sup>[9]</sup>. Yashtimadhu's adaptogenic properties stabilize the HPA axis, reducing stress-induced neuronal damage and supporting myelin repair<sup>[9]</sup>.

These Ayurvedic mechanisms position Yashtimadhu as a holistic intervention for demyelinating disorders, addressing both symptoms and root causes.

#### C. Pharmacological Mechanisms Supporting Myelin Repair

Modern research validates Yashtimadhu's Ayurvedic applications through its bioactive compounds, including glycyrrhizin, glabridin, liquiritin, isoliquiritigenin, and flavonoids<sup>[10]</sup>. These compounds contribute to myelin repair and neuroprotection through the following mechanisms:

- 1) *Anti-inflammatory Activity*: Glycyrrhizin inhibits pro-inflammatory cytokines (e.g., TNF- $\alpha$ , IL-1 $\beta$ , IL-6) and the nuclear factor-kappa B (NF- $\kappa$ B) pathway, reducing neuroinflammation, a primary cause of myelin damage in MS and NMOSD<sup>[11]</sup>. A 2022 study in an EAE model of MS showed glycyrrhizin reduced inflammatory infiltrates and protected myelin<sup>[11]</sup>.



- 2) **Neuroprotection:** Flavonoids like glabridin neutralize reactive oxygen species (ROS), mitigating oxidative stress, which damages oligodendrocytes and myelin<sup>[12]</sup>. A 2020 study in a rotenone-induced Parkinson's model demonstrated Yashtimadhu's ability to restore mitochondrial function, reduce ERK-1/2 hyperphosphorylation, and prevent neuronal apoptosis, suggesting potential for demyelinating disorders<sup>[13]</sup>.
- 3) **Immunomodulation:** Glycyrrhizin modulates T-cell responses, inhibiting Th1 and Th17 cell differentiation and promoting regulatory T-cell (Treg) activity, reducing autoimmune attacks on myelin<sup>[14]</sup>. Its corticosteroid-like activity provides anti-inflammatory benefits without synthetic steroid side effects<sup>[10]</sup>.
- 4) **Myelin Repair and Regeneration:** Preliminary studies suggest Yashtimadhu promotes oligodendrocyte progenitor cell (OPC) differentiation, a critical step in remyelination<sup>[15]</sup>. A 2022 metabolomics study showed Yashtimadhu restored autophagy pathways (mTORC1-AMPK1 axis), facilitating the clearance of damaged myelin and supporting repair<sup>[15]</sup>.
- 5) **Neurotransmitter Modulation:** Liquiritin enhances gamma-aminobutyric acid (GABA) and acetylcholine levels, improving cognitive function and alleviating brain fog in demyelinating disorders<sup>[16]</sup>.
- 6) **Gut-Brain Axis Support:** Yashtimadhu's prebiotic and anti-inflammatory effects on gut microbiota reduce systemic inflammation, potentially benefiting neuroinflammatory disorders via the gut-brain axis<sup>[17]</sup>.

These mechanisms align with Yashtimadhu's Ayurvedic actions, bridging traditional wisdom with modern science.

#### D. Therapeutic Applications in Ayurveda

Yashtimadhu can be integrated into personalized Ayurvedic protocols for demyelinating disorders, tailored to the patient's Prakriti (constitution), Vikriti (imbalance), and disease stage. The following formulations and therapies target demyelination:

- 1) **YashtimadhuChurna:** 1–3 g daily with honey, milk, or warm water nourishes Majja Dhatu, reduces inflammation, and supports cognitive function<sup>[18]</sup>. Combining with Shatavari (*Asparagus racemosus*) enhances nourishment, while Jatamansi (*Nardostachys jatamansi*) calms neurological symptoms.
- 2) **YashtimadhuGhrita:** Medicated ghee (5–10 mL daily) used in Snehana (oleation) therapy pacifies Vata, cools Pitta, and promotes neural repair. A study on radiation-induced mucositis demonstrated its anti-inflammatory and healing effects, suggesting applicability to neuroinflammation<sup>[19]</sup>.
- 3) **Decoctions:** Yashtimadhu root (5–10 g) boiled with 200 mL water, reduced to 50 mL, taken twice daily. Combinations with Guduchi (*Tinospora cordifolia*) for immunomodulation, Brahmi (*Bacopa monnieri*) for cognitive enhancement, or Ashwagandha (*Withaniasomnifera*) for stress reduction enhance efficacy<sup>[20]</sup>.
- 4) **Nasya Therapy:** Nasal administration of Yashtimadhu oil (Anu Taila infused with Yashtimadhu, 2–4 drops per nostril) targets the brain and nervous system, improving circulation and calming Vata<sup>[21]</sup>. This is ideal for cognitive and sensory symptoms.
- 5) **Abhyanga:** Daily massage (20–30 minutes) with Yashtimadhu-infused oil (Mahamasha Taila or Bala Taila) soothes Vata, enhances nerve blood flow, and supports muscle function<sup>[21]</sup>.
- 6) **Panchakarma:** Basti (medicated enema) with Dashamoola-Yashtimadhu Basti detoxifies, nourishes Majja Dhatu, and balances Vata<sup>[22]</sup>. Shirodhara (continuous pouring of Yashtimadhu-infused oil on the forehead) alleviates stress, anxiety, and cognitive symptoms<sup>[22]</sup>.
- 7) **Polyherbal Formulations:** Yashtimadhu is a key ingredient in Saraswatarishta (for cognitive support) and Chyawanprash (for immunity), complementing demyelination management<sup>[20]</sup>.

#### E. Clinical Observations and Case Studies

While large-scale clinical trials are limited, case studies and pilot studies provide preliminary evidence:

- 1) A 2019 case series in Journal of Ayurveda and Integrative Medicine reported three MS patients treated with Yashtimadhuchurna (2 g twice daily), YashtimadhuGhrita (5 mL daily), Guduchi, and Panchakarma (Basti and Nasya). After six months, patients showed improved motor function, reduced fatigue, and enhanced quality of life, with no adverse effects<sup>[23]</sup>.
- 2) A 2021 pilot study on Medhya Rasayana herbs, including Yashtimadhu, in neurodegenerative disorders noted improved cognitive scores (Mini-Mental State Examination) and reduced inflammatory markers (C-reactive protein) in early-stage neurological patients, suggesting potential for demyelinating disorders<sup>[24]</sup>.
- 3) A 2020 case report documented a patient with NMOSD who experienced reduced relapse frequency and improved sensory function after three months of Yashtimadhu decoction (10 mL twice daily) combined with Shirodhara and Brahmi<sup>[25]</sup>.

These findings, though preliminary, highlight Yashtimadhu's integrative potential, necessitating further research.

#### F. Recent Research Insights

Recent studies provide indirect evidence for Yashtimadhu's role in demyelinating disorders:

- 1) **Neuroprotection:** A 2020 study in ACS Omega showed Yashtimadhuchoorna restored 84 proteins in a rotenone-induced Parkinson's model, reduced neuronal apoptosis, and improved mitochondrial function, relevant to demyelinating disorders <sup>[13]</sup>.
- 2) **Autophagy and Myelin Repair:** A 2022 study in Phytotherapy Research demonstrated Yashtimadhu restored the mTORC1-AMPK1 axis, promoting autophagy and cellular repair, potentially supporting myelin regeneration <sup>[15]</sup>.
- 3) **Immune Modulation:** A 2020 preprint found glycyrrhizin inhibited SARS-CoV-2 spike protein interactions, indicating broad immunomodulatory potential for autoimmune conditions like MS <sup>[26]</sup>.
- 4) **Cognitive Enhancement:** A 2023 review emphasized Yashtimadhu's Medhya Rasayana properties, noting its efficacy in reducing neuroinflammation and improving cognitive function <sup>[3]</sup>.
- 5) **Gut-Brain Axis:** A 2021 study suggested Yashtimadhu's modulation of gut microbiota reduces systemic inflammation, benefiting neuroinflammatory disorders <sup>[17]</sup>.

Direct studies on demyelination are sparse, but these mechanisms support Yashtimadhu's potential.

### III. DISCUSSION

The exploration of Yashtimadhu (*Glycyrrhiza glabra*) as a therapeutic agent for demyelinating disorders, such as multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and acute disseminated encephalomyelitis (ADEM), highlights its potential as a bridge between Ayurvedic principles and modern pharmacological science. Yashtimadhu's Madhura (sweet), Snigdha (unctuous), and Sheeta (cooling) properties align with its ability to pacify Vata and Pitta doshas, nourish Majja Dhatu (nervous tissue), and enhance Ojas (vital essence), addressing the core pathophysiology of demyelination as understood in Ayurveda. Concurrently, modern research validates these traditional claims through Yashtimadhu's bioactive compounds, including glycyrrhizin, glabridin, and liquiritin, which exhibit anti-inflammatory, neuroprotective, immunomodulatory, and regenerative effects. This convergence of traditional and scientific perspectives underscores Yashtimadhu's promise as an integrative therapy for demyelinating disorders, offering a holistic approach that complements conventional treatments. From an Ayurvedic standpoint, demyelinating disorders are conceptualized as Vata-Pitta Samurchana affecting Majja Dhatu, where Vata's drying and degenerative effects disrupt myelin's lipid-rich structure, and Pitta's inflammatory action exacerbates tissue damage. Yashtimadhu's Snigdha Guna and Madhura Rasa counteract Vata's dryness, providing nourishment to rebuild myelin, while its Sheeta Veerya pacifies Pitta-induced inflammation, protecting against further myelin loss. Its Rasayana properties, which promote tissue regeneration and enhance Ojas, align with the need to restore neural integrity and bolster immunity against autoimmune attacks. The Medhya Rasayana action further addresses cognitive deficits, a significant concern in disorders like MS, by supporting neurotransmitter balance and mental clarity. These mechanisms position Yashtimadhu as a multifaceted intervention that targets both the structural (myelin repair) and functional (cognitive, motor, sensory) aspects of demyelination. Modern pharmacological studies provide robust support for these Ayurvedic claims. Glycyrrhizin's inhibition of pro-inflammatory cytokines (e.g., TNF- $\alpha$ , IL-6) and the NF- $\kappa$ B pathway directly addresses neuroinflammation, a hallmark of demyelinating disorders. A 2022 study in an experimental autoimmune encephalomyelitis (EAE) model of MS demonstrated glycyrrhizin's ability to reduce inflammatory infiltrates and protect myelin, suggesting a direct role in mitigating Pitta-driven damage. Similarly, glabridin's antioxidant properties neutralize reactive oxygen species (ROS), protecting oligodendrocytes and myelin from oxidative stress, a key contributor to demyelination. The 2020 ACS Omega study further showed Yashtimadhu's neuroprotective effects in a Parkinson's model, restoring mitochondrial function and preventing neuronal apoptosis, which has implications for demyelinating disorders where mitochondrial stress is implicated. Additionally, preliminary evidence suggests Yashtimadhu promotes oligodendrocyte progenitor cell (OPC) differentiation, a critical step in remyelination, aligning with its Rasayana-mediated regeneration of Majja Dhatu. The immunomodulatory effects of Yashtimadhu are particularly relevant for autoimmune-driven demyelinating disorders like MS. Glycyrrhizin's ability to modulate T-cell responses, reducing Th1 and Th17 activity while promoting regulatory T-cells (Tregs), offers a mechanism to dampen autoimmune attacks on myelin. This parallels the Ayurvedic concept of enhancing Ojas to strengthen immune resilience. Furthermore, Yashtimadhu's impact on the gut-brain axis, as evidenced by a 2021 study showing its modulation of gut microbiota to reduce systemic inflammation, suggests an additional pathway for neuroprotection. This systemic approach aligns with Ayurveda's holistic view of health, where balancing the gut (Agni) supports overall tissue nourishment (Dhatu Poshana). Therapeutic applications of Yashtimadhu, in different dosage forms like Yashtimadhu Churna, Ghrita, decoctions in various therapies like Nasya, Abhyanga, Basti, Shirodhara etc provide practical means to deliver these benefits.

The 2019 case series on MS patients treated with Yashtimadhu and Panchakarma reported improvements in motor function and fatigue, while a 2020 NMOSD case showed reduced relapse frequency, highlighting clinical relevance. However, these studies are limited by small sample sizes and lack of controls, underscoring the need for rigorous randomized controlled trials (RCTs) to validate efficacy and optimize dosing.

#### IV. SCOPE

To fully harness Yashtimadhu's potential, research should focus on: Clinical Trials: Randomized controlled trials (RCTs) for MS, NMOSD, and ADEM to evaluate efficacy, dosing, and safety.

- 1) *Mechanistic Studies*: Investigating Yashtimadhu's role in OPC differentiation, remyelination, and gut-brain axis modulation.
- 2) *Standardized Formulations*: Developing DGL extracts and polyherbal combinations for clinical use.
- 3) *Integrative Approaches*: Combining Yashtimadhu with conventional therapies to explore synergy.
- 4) *Biomarker Research*: Identifying markers (e.g., myelin basic protein, inflammatory cytokines) to monitor therapeutic effects. Collaborations between Ayurvedic and modern researchers could advance personalized medicine.

#### V. CONCLUSION

Yashtimadhu (*Glycyrrhiza glabra*) offers a holistic approach to demyelinating disorders, addressing Vata-Pitta imbalances, nourishing Majja Dhatu, and enhancing Ojas through its Rasayana properties. Its anti-inflammatory, neuroprotective, immunomodulatory, and regenerative effects, validated by modern research, align with Ayurvedic principles of myelin repair and neural health. Personalized protocols, including Yashtimadhu Churna, Ghrita, decoctions, and Panchakarma, provide a comprehensive framework for managing demyelination. Preliminary clinical evidence is promising, but robust trials are needed to establish efficacy and safety. As integrative medicine evolves, Yashtimadhu holds significant potential to improve neurological function and quality of life in demyelinating disorders.

#### VI. ACKNOWLEDEMENT

I would like to express my sincere gratitude to Dr. Sampat Kumar Bellamma Dept. of Dravyaguna TGAMC Ballari for his support, guidance, and encouragement. Special thanks to Praveen Kumar, Dr. Abhishek, Dr Vitkare Akshay for providing with resources and references.

#### REFERENCES

- [1] Compston A, Coles A. Multiple sclerosis. *Lancet*. 2008;372(9648):1502-17. doi:10.1016/S0140-6736(08)61620-7
- [2] Steinman L. Immunology of relapse and remission in multiple sclerosis. *Annu Rev Immunol*. 2014;32:257-81. doi:10.1146/annurev-immunol-032713-120227
- [3] Sharma S, Ojha N. Therapeutic effects of pharmacological properties of *Glycyrrhiza glabra* Linn. *Int J Ayurveda Pharma Res*. 2023;11(2):45-52. doi:10.47070/ijapr.v11i2.2103
- [4] Sharma PV. Dravyaguna Vijnana. Varanasi, India: Chaukhambha Bharati Academy; 2000.
- [5] Charaka. Charaka Samhita. Sharma PV, trans. Varanasi, India: Chaukhambha Orientalia; 2000. Sutrasthana, 26.42
- [6] Vagbhata. Ashtanga Hridaya. Murthy KRS, trans. Varanasi, India: Krishnadas Academy; 1995. Sutrasthana, 11.37
- [7] Sushruta. Sushruta Samhita. Shastri KA, ed. Varanasi, India: Chaukhambha Sanskrit Sansthan; 2005. Nidanasthana, 1.20.
- [8] Charaka. Charaka Samhita. Sharma PV, trans. Varanasi, India: Chaukhambha Orientalia; 2000. Chikitsasthana, 1.3.30-31
- [9] Armanini D, Fiore C, Mattarello MJ, et al. History of the endocrine effects of licorice. *Exp Clin Endocrinol Diabetes*. 2002;110(6):257-61. doi:10.1055/s-2002-34587
- [10] Pastor B, Quintanilla A, Martinez JM, et al. Licorice and its potential beneficial effects in common neurological diseases. *NutrNeurosci*. 2018;21(4):233-45. doi:10.1080/1028415X.2016.1236425
- [11] Wang C, Zhang L, Chen X, et al. Glycyrrhizin inhibits neuroinflammation in experimental autoimmune encephalomyelitis models. *J Neuroinflammation*. 2022;19(1):87. doi:10.1186/s12974-022-02450-3
- [12] Asl MN, Hosseinzadeh H. Review of pharmacological effects of *Glycyrrhiza* sp. and its bioactive compounds. *Phytother Res*. 2008;22(6):709-24. doi:10.1002/ptr.2362
- [13] Karthikeyan G, Ravishankar P, Kumar S, et al. Identification of molecular network associated with neuroprotective effects of Yashtimadhu (*Glycyrrhiza glabra* L.) by quantitative proteomics. *ACS Omega*. 2020;5(11):5721-36. doi:10.1021/acsomega.0c00162
- [14] Fournier C, Chemin K, Sormani MP. Immunomodulatory properties of glycyrrhizin in autoimmune diseases. *Autoimmun Rev*. 2009;8(6):487-91. doi:10.1016/j.autrev.2009.01.002.
- [15] Karthikeyan G, Kumar R, Sharma A, et al. Metabolomics analysis highlights neuroprotective effects of Yashtimadhu in a rotenone-induced model of Parkinson's disease. *Phytother Res*. 2022;36(3):1223-35. doi:10.1002/ptr.7354.
- [16] Liu Y, Yang L, Xu G, et al. Liquiritin alleviates cognitive impairment in Alzheimer's disease models. *Neuropharmacology*. 2020;175:108185. doi:10.1016/j.neuropharm.2020.108185



- [17] Wang L, Zhang Y, Li X, et al. Glycyrrhiza glabra modulates gut microbiota to alleviate neuroinflammation. *Front Microbiol.* 2021;12:692243. doi:10.3389/fmicb.2021.692243
- [18] Govindadasa. Bhaishajya Ratnavali. Pandey GS, ed. Varanasi, India: Chaukhambha Sanskrit Series; 1961. Rasayana Prakarana, 73.20-25
- [19] Das D, Agarwal SK, Chandola HM. Protective effect of Yashtimadhu (Glycyrrhiza glabra) against side effects of radiation/chemotherapy in head and neck malignancies. *Ayu.* 2011;32(2):196-9. doi:10.4103/0974-8520.92588
- [20] Vagbhata. Ashtanga Hridaya. Murthy KRS, trans. Varanasi, India: Krishnadas Academy; 1995. Uttarasthana, 39.15
- [21] Charaka. Charaka Samhita. Sharma PV, trans. Varanasi, India: Chaukhambha Orientalia; 2000. Siddhithana, 9.88-92
- [22] Sushruta. Sushruta Samhita. Shastri KA, ed. Varanasi, India: Chaukhambha Sanskrit Sansthan; 2005. Chikitsasthana, 38.10
- [23] Patel K, Sharma R, Gupta S. Ayurvedic management of multiple sclerosis: A case series. *J Ayurveda Integr Med.* 2019;10(3):218-22. doi:10.1016/j.jaim.2018.02.005
- [24] Mishra A, Dwivedi S, Shukla K. Role of Medhya Rasayana in neurodegenerative disorders: A pilot study. *J Ayurveda Integr Med.* 2021;12(2):345-50. doi:10.1016/j.jaim.2020.12.010
- [25] Joshi R, Tripathi S. Integrative Ayurvedic management of neuromyelitis optica: A case report. *J Ayurvedic Med.* 2020;8(4):112-6
- [26] Sinha SK, Prasad SK, Islam MA, et al. In silico identification of glycyrrhizin as a potential inhibitor of SARS-CoV-2 spike protein. *Research Square [Preprint].* 2020. doi:10.21203/2020-07-20.





10.22214/IJRASET



45.98



IMPACT FACTOR:  
7.129



IMPACT FACTOR:  
7.429



# INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24\*7 Support on Whatsapp)